348 related articles for article (PubMed ID: 34780312)
1. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
[No Abstract] [Full Text] [Related]
2. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.
MacKinnon N; Lane D; Scheuermeyer F; Kaczorowski J; Dong K; Orkin AM; Daoust R; Moe J; Andolfatto G; Klaiman M; Yan J; Koh JJ; Crowder K; Atkinson P; Savage D; Stempien J; Besserer F; Wale J; Kestler A
PLoS One; 2024; 19(2):e0297084. PubMed ID: 38315732
[TBL] [Abstract][Full Text] [Related]
4. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021.
Chua KP; Dahlem CHY; Nguyen TD; Brummett CM; Conti RM; Bohnert AS; Dora-Laskey AD; Kocher KE
Ann Emerg Med; 2022 Mar; 79(3):225-236. PubMed ID: 34802772
[TBL] [Abstract][Full Text] [Related]
5. Interrupted Time Series of User-centered Clinical Decision Support Implementation for Emergency Department-initiated Buprenorphine for Opioid Use Disorder.
Holland WC; Nath B; Li F; Maciejewski K; Paek H; Dziura J; Rajeevan H; Lu CC; Katsovich L; D'Onofrio G; Melnick ER
Acad Emerg Med; 2020 Aug; 27(8):753-763. PubMed ID: 32352206
[TBL] [Abstract][Full Text] [Related]
6. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
7. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
8. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
10. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
[TBL] [Abstract][Full Text] [Related]
12. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
14. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
15. Exploratory Economic Evaluation of Buprenorphine Treatment in Opioid Use Disorder.
Elarabi HF; Al Ghaferi H; Hasan N; Lee AJ; Shawky M; Al Kathiri H; Elrasheed A; Al Maamari S; Gawad TA; Radwan D; Adem A; Marsden J
J Ment Health Policy Econ; 2021 Sep; 24(3):89-95. PubMed ID: 34554106
[TBL] [Abstract][Full Text] [Related]
16. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
Shearer D; Young S; Fairbairn N; Brar R
Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
18. The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.
D'Onofrio G; Hawk KF; Herring AA; Perrone J; Cowan E; McCormack RP; Dziura J; Taylor RA; Coupet E; Edelman EJ; Pantalon MV; Owens PH; Martel SH; O'Connor PG; Van Veldhuisen P; DeVogel N; Huntley K; Murphy SM; Lofwall MR; Walsh SL; Fiellin DA
Contemp Clin Trials; 2021 May; 104():106359. PubMed ID: 33737199
[TBL] [Abstract][Full Text] [Related]
19. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
[TBL] [Abstract][Full Text] [Related]
20. Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder.
D'Onofrio G; Edelman EJ; Hawk KF; Chawarski MC; Pantalon MV; Owens PH; Martel SH; Rothman R; Saheed M; Schwartz RP; Cowan E; Richardson L; Salsitz E; Lyons MS; Freiermuth C; Wilder C; Whiteside L; Tsui JI; Klein JW; Coupet E; O'Connor PG; Matthews AG; Murphy SM; Huntley K; Fiellin DA
JAMA Netw Open; 2023 Apr; 6(4):e235439. PubMed ID: 37017967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
